文献速递糖尿病

二甲双胍通过增加肠促胰岛素改善青少年2型糖尿病血糖,且不依赖于糖异生变化

Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes.
PubMed 文献 · Diabetologia · 2020-07-29

本病例对照观察研究纳入未使用二甲双胍的青少年2型糖尿病患者18例和糖耐量正常青少年10例,其中9例2型糖尿病青少年接受二甲双胍治疗3个月前后对比。结果显示二甲双胍降低餐后2小时血糖,并升高胰岛素生成指数、空腹完整胰高血糖素样肽-1及肽YY,而葡萄糖生成率、糖异生和脂解速率无变化。

要点

  • 二甲双胍降低2型糖尿病青少年2小时血糖(11.4 vs 9.9 mmol/l,p=0.04)。
  • 二甲双胍使胰岛素生成指数中位数由1.39升至1.43(p=0.04)。
  • 空腹完整胰高血糖素样肽-1由0.3升至1.0 pmol/l(p=0.02),肽YY亦升高。

核心结论

  • 二甲双胍改善青少年2型糖尿病餐后血糖并增加肠促胰岛素,而胰岛素敏感性和糖异生无变化,支持肠胰岛轴机制。

研究设计与样本

  • 病例对照观察研究,纳入未使用二甲双胍的青少年2型糖尿病患者18例与糖耐量正常青少年10例,采用2天研究方案。
  • 其中9例2型糖尿病青少年接受二甲双胍治疗3个月后,以相同2天方案复评。

主要发现

  • 与糖耐量正常组相比,2型糖尿病组空腹血糖较高(7.8±2.5 vs 5.1±0.3 mmol/l,p=0.002),2小时血糖较高(13.8±4.5 vs 5.9±0.9 mmol/l,p=0.001)。
  • 2型糖尿病组绝对糖异生率较高(10.0±1.7 vs 7.2±1.1 μmol kgFFM⁻¹ min⁻¹,p<0.001),全身脂解率较高(5.2±0.9 vs 4.0±1.4 μmol kgFFM⁻¹ min⁻¹,p<0.01),空腹完整胰高血糖素样肽-1较低(0.5±0.5 vs 1.3±0.7 pmol/l,p<0.01)。
  • 二甲双胍降低2小时血糖(用药前11.4±2.8 vs 用药后9.9±1.9 mmol/l,p=0.04),升高胰岛素生成指数中位数(用药前1.39[0.89-1.47] vs 用药后1.43[0.88-2.70],p=0.04)。
  • 二甲双胍升高空腹完整胰高血糖素样肽-1(用药前0.3±0.2 vs 用药后1.0±0.7 pmol/l,p=0.02)、空腹肽YY(用药前6.3±2.2 vs 用药后10.5±4.3 pmol/l,p<0.01)和2小时肽YY(用药前6.6±2.9 vs 用药后9.0±4.0 pmol/l,p<0.01)。
  • 用药前后BMI、胰岛素敏感性、葡萄糖生成率(15.0±3.9 vs 14.9±2.2 μmol kgFFM⁻¹ min⁻¹,p=0.84)、绝对糖异生率(9.9±1.8 vs 9.7±1.7 μmol kgFFM⁻¹ min⁻¹,p=0.76)和全身脂解率(5.0±0.7 vs 5.3±1.3 μmol kgFFM⁻¹ min⁻¹,p=0.20)无变化。

关键数值与推荐

  • 2小时完整胰高血糖素样肽-1用药前0.4±0.2 vs 用药后1.2±0.9 pmol/l,p=0.06,未达统计学显著。
  • 用药后2型糖尿病青少年完整胰高血糖素样肽-1和肽YY浓度与糖耐量正常青少年相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Metformin is the only approved oral agent for youth with type 2 diabetes but its mechanism of action remains controversial. Recent data in adults suggest a primary role for the enteroinsular pathway, but there are no data in youth, in whom metformin efficacy is only ~50%. Our objectives were to compare incretin concentrations and rates of glucose production and gluconeogenesis in youth with type 2 diabetes before and after short-term metformin therapy compared with peers with normal glucose tolerance (NGT). METHODS: This is a case-control observational study in youth with type 2 diabetes who were not on metformin (n = 18) compared with youth with NGT (n = 10) who were evaluated with a 2 day protocol. A 75 g OGTT was administered to measure intact glucagon-like 1 peptide (iGLP-1), gastric inhibitory polypeptide (GIP) and peptide YY (PYY). Insulinogenic index (IGI) and whole-body insulin sensitivity were calculated using glucose and insulin levels from the OGTT. Basal rates of gluconeogenesis (2H2O), glucose production ([6,6-2H2]glucose) and whole-body lipolysis ([2H5]glycerol) were measured after an overnight fast on study day 2. Youth with type 2 diabetes (n = 9) were subsequently evaluated with an identical 2 day protocol after 3 months on the metformin study. RESULTS: Compared with individuals with NGT, those with type 2 diabetes had higher fasting (7.8 ± 2.5 vs 5.1 ± 0.3 mmol/l, mean ± SD p = 0.002) and 2 h glucose concentrations (13.8 ± 4.5 vs 5.9 ± 0.9 mmol/l, p = 0.001), higher rates of absolute gluconeogenesis (10.0 ± 1.7 vs 7.2 ± 1.1 μmol [kg fat-free mass (FFM)]-1 min-1, p < 0.001) and whole-body lipolysis (5.2 ± 0.9 vs 4.0 ± 1.4 μmol kgFFM-1 min-1, p < 0.01), but lower fasting iGLP-1 concentrations (0.5 ± 0.5 vs 1.3 ± 0.7 pmol/l, p < 0.01). Metformin decreased 2 h glucose (pre metformin 11.4 ± 2.8 vs post metformin 9.9 ± 1.9 mmol/l, p = 0.04) and was associated with ~20-50% increase in IGI (median [25th-75th percentile] pre 1.39 [0.89-1.47] vs post 1.43 [0.88-2.70], p = 0.04), fasting iGLP-1 (pre 0.3 ± 0.2 vs post 1.0 ± 0.7 pmol/l, p = 0.02), 2 h iGLP (pre 0.4 ± 0.2 vs post 1.2 ± 0.9 pmol/l, p = 0.06), fasting PYY (pre 6.3 ± 2.2 vs post 10.5 ± 4.3 pmol/l, p < 0.01) and 2 h PYY (pre 6.6 ± 2.9 vs post 9.0 ± 4.0 pmol/l, p < 0.01). There was no change in BMI, insulin sensitivity or GIP concentrations pre vs post metformin. There were no differences pre vs post metformin in rates of glucose production (15.0 ± 3.9 vs 14.9 ± 2.2 μmol kgFFM-1 min-1, p = 0.84), absolute gluconeogenesis (9.9 ± 1.8 vs 9.7 ± 1.7 μmol kgFFM-1 min-1, p = 0.76) or whole-body lipolysis (5.0 ± 0.7 vs 5.3 ± 1.3 μmol kgFFM-1 min-1, p = 0.20). Post metformin iGLP-1 and PYY concentrations in youth with type 2 diabetes were comparable to levels in youth with NGT. CONCLUSIONS/INTERPRETATION: Overall, the improved postprandial blood glucose levels and increase in incretins observed in the absence of changes in insulin sensitivity and gluconeogenesis, support an enteroinsular mechanistic pathway in youth with type 2 diabetes treated with short-term metformin.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Cravalho CKL, Meyers AG, Mabundo LS, et al. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes. Diabetologia. 2020. PMID: 32728891. doi:10.1007/s00125-020-05236-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。